{"entity":{"id":"alx-oncology","kind":"company","name":"ALX Oncology","aka":["ALX Oncology Holdings"],"tldr":"ALX Oncology is a Californian biotechnology company developing evorpacept, a CD47-blocking fusion protein designed to remove the 'do not eat me' signal so that antibodies such as trastuzumab can recruit macrophages against HER2-positive gastric cancer.","summary":"ALX Oncology, based in South San Francisco, develops evorpacept (ALX148), an engineered SIRP-alpha fusion protein that blocks CD47 without the red-cell toxicity of earlier CD47 antibodies, so it can be combined with tumour-targeting antibodies to enhance macrophage attack. Its lead trial ASPEN-06 tests evorpacept with trastuzumab, ramucirumab and paclitaxel in previously treated HER2-positive gastric cancer, and the company is studying the drug in other antibody combinations. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://alxoncology.com/"},{"label":"ClinicalTrials.gov: trials led by ALX Oncology","url":"https://clinicaltrials.gov/search?lead=ALX%20Oncology"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["gastric"],"sections":["immunotherapy"],"technologies":[],"targets":["cd47"],"drugs":["evorpacept"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["aspen-06","nct04675294","nct04675333","nct07007559"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://alxoncology.com/","stage":"public","investors":[],"funding":[]},"route":"/companies/alx-oncology/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"target":[{"id":"cd47","kind":"target","name":"CD47","route":"/targets/cd47/"}],"drug":[{"id":"evorpacept","kind":"drug","name":"Evorpacept","route":"/drugs/evorpacept/"}],"trial":[{"id":"aspen-06","kind":"trial","name":"A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)","route":"/trials/aspen-06/"},{"id":"nct07007559","kind":"trial","name":"ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer","route":"/trials/nct07007559/"},{"id":"nct04675333","kind":"trial","name":"Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)","route":"/trials/nct04675333/"},{"id":"nct04675294","kind":"trial","name":"Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)","route":"/trials/nct04675294/"},{"id":"nct05868226","kind":"trial","name":"PRE-ISPY Phase I/II Oncology Platform Program","route":"/trials/nct05868226/"}]}}